#inlicensing

Last week Marie and I were attending BioTrinity in NewBury UK. A real nice venue and very well organized seminar. 

The main tendancy was around venturing & inlicensing with a good balance of biotech, big pharma.and venture capital representatives. A panel discussion "Innovative Financing and Deferred Consideration, Essential Parts of Deal Terms?" chaired by John Carroll from FierceBiotech and panellists David Colpman (Shire Pharmaceuticals), Tim Herpin(AstraZeneca), Stewart Kay (GlaxoSmithKline), Patrick Verheyen (Johnson & Johnson) and Scott Cuthill (Ipsen Biopharm Ltd) highlighted that. There was some moemntum when what was evangelized by the big parties and what happened in reality with the engagement models still show discrepencies. But the momentum is there, now.

We met quite some folks from biotech and pharma and got great feedback on our demo's. Looks the workshop confirmed we are ready for the market. Our dev team is prepping that together with sales and marketing to make it happen. 

Next to that our tool is really getting momentum not only with visitors at our booth but also with a pharmaTV interview, follow up and a potential editorial in Pharma publications (IPI).

The team has a lot to follow up which is a good thing and made this a successful business trip.